Sage Journals: Discover world-class research

Abstract

Influenza virus-like particles (VLPs) are effective vaccines against influenza infection, which can be produced either in insect cells by recombinant baculovirus (BV) infection or in mammalian cells by DNA plasmid transfection. However, VLPs produced from baculovirus/insect cells are difficult to purify due to baculovirus contamination; VLPs produced by plasmid transfection are limited by scale-up capability. In this study, a BacMam BV, in which three CMV-promoters drive the hemagglutinin, neuraminidase, and matrix of influenza virus was constructed. This baculovirus can deliver these genes into mammalian cells/hosts and subsequently influenza VLPs can be produced and secreted from transduced cells. Transduction conditions were optimized and influenza VLPs were purified from transduced 293T cells. Mice were vaccinated with BV transduction-produced VLPs, plasmid transfection-produced VLPs, and BacMam BV. Two vaccinations of each vaccine induced high hemagglutination-inhibition (HAI) titers and prevented influenza virus infection. In contrast, following a single vaccination, all mice vaccinated with each vaccine had significantly lower lung viral titers compared to unvaccinated mice. Remarkably, mice vaccinated with a single dose of BV transduction-produced VLPs survived challenge, whereas mice vaccinated with one dose of BacMam BV- or plasmid transfection-produced VLPs had 60–80% survival. This finding is particularly significant for producing easily purified VLPs. The BacMam system is an alternative strategy for VLP production, which is easy to scale up and purify. Besides, BacMam BV can be used as a gene delivery vector to produce VLPs in vivo, to stimulate immune responses.

Get full access to this article

View all access options for this article.

References

Pinto

, Edwards

, Castle

et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis, 2003; 188:327–338.

Emeny

, Wheeler

, Jansen

et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol, 2002; 76:7832–7842.

Ross

, Mahmood

, Crevar

et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PloS One, 2009; 4:e6032.

Haynes

. Influenza virus-like particle vaccines. Exp Review Vaccines, 2009; 8:435–445.

Grgacic

, Anderson

. Virus-like particles: passport to immune recognition. Methods, 2006; 40:60–65.

Pushko

, Tumpey

, Bu

et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine, 2005; 23:5751–5759.

Quan

, Huang

, Compans

, Kang

. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol, 2007; 81:3514–3524.

Bright

, Carter

, Daniluk

et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine, 2007; 25:3871–3878.

Bright

, Carter

, Crevar

et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PloS One, 2008; 3:e1501.

10.

Haynes

, Dokken

, Wiley

et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine, 2009; 27:530–541.

11.

Volkman

, Goldsmith

. In vitro survey of autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl Environmental Microbiol, 1983; 45:1085–1093.

12.

Carbonell

, Klowden

, Miller

. Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. J Virol, 1985; 56:153–160.

13.

Hofmann

, Sandig

, Jennings

et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA, 1995; 92:10099–10103.

14.

Boyce

, Bucher

. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA, 1996; 93:2348–2352.

15.

Kost

, Condreay

. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol, 2002; 20:173–180.

16.

van Loo

, Fortunati

, Ehlert

et al. Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids. J Virol, 2001; 75:961–970.

17.

Sarkis

, Serguera

, Petres

et al. Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci USA, 2000; 97:14638–14643.

18.

Pieroni

, La Monica

. Towards the use of baculovirus as a gene therapy vector. Curr Opin Molec Therapeutics, 2001; 3:464–467.

19.

Chuang

, Sung

, Hwang

et al. Baculovirus as a new gene delivery vector for stem cell engineering and bone tissue engineering. Gene Therapy, 2007; 14:1417–1424.

20.

Boulaire

, Zhao

, Wang

. Gene expression profiling to define host response to baculoviral transduction in the brain. J Neurochem, 2009; 109:1203–1214.

21.

, Fang

, Wu

et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Molec Immunol, 2009; 46:2210–2217.

22.

Facciabene

, Aurisicchio

, La Monica

. Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol, 2004; 78:8663–8672.

23.

Strauss

, Huser

, Ni

et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol Ther, 2007; 15:193–202.

24.

Tani

, Abe

, Matsunaga

et al. Baculovirus vector for gene delivery and vaccine development. Future Virol, 2008; 3:35–43.

25.

Tang

, Lu

, Ross

. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine, 2010; 28:6821–6831.

26.

Hsu

, Ho

, Wang

, Hu

. Investigation of optimal transduction conditions for baculovirus-mediated gene delivery into mammalian cells. Biotechnol Bioengineering, 2004; 88:42–51.

27.

Tani

, Limn

, Yap

et al. In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol, 2003; 77:9799–9808.

28.

Condreay

, Witherspoon

, Clay

, Kost

. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA, 1999; 96:127–132.

29.

Abramoff

, Magelhaes

, Ram

. Image Processing with ImageJ. Biophotonics International, 2004; 11:36–42.

30.

Barsoum

, Brown

, McKee

, Boyce

. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Human Gene Ther, 1997; 8:2011–2018.

31.

Kenoutis

, Efrose

, Swevers

et al. Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. J Virol, 2006; 80:4135–4146.

32.

Killian

. Hemagglutination assay for the avian influenza virus. Methods Molec Biology, 2008; 436:47–52.

33.

1997 Committee for Human Medicinal Products: Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products.

34.

Ludwig

, Wagner

. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol, 2007; 18:537–545.

35.

Roy

, Noad

. Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines, 2008; 4:5–12.

36.

Shiosaki

, Takata

, Nishimura

et al. Production of hepatitis B virion-like particles in yeast. Gene, 1991; 106:143–149.

37.

Robertson

, Harrap

, Longworth

. Baculovirus morphogenesis: the acquisition of the virus envelope. J Invertebrate Pathol, 1974; 23:248–251.

38.

Vicente

, Peixoto

, Carrondo

, Alves

. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Therapy, 2009; 16:766–775.

39.

Garland

, Hernandez-Avila

, Wheeler

et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med., 2007; 356:1928–1943.

40.

Rueda

, Fominaya

, Langeveld

et al. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine, 2000; 19:726–734.

41.

Kosukegawa

, Arisaka

, Takayama

et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochimica Biophysica Acta, 1996; 1290:37–45.

42.

, Bentley

, Edwards

, Vakharia

. Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography. Biotechnol Bioengineering, 1999; 63:721–729.

43.

, Tsai

, Chang

, Huang

. Enhancement and prolongation of baculovirus-mediated expression in mammalian cells: focuses on strategic infection and feeding. Biotechnol Progress, 2003; 19:373–379.

44.

Scott

, Modha

, Rhodes

et al. Efficient expression of secreted proteases via recombinant BacMam virus. Protein Expression Purification, 2007; 52:104–116.

45.

Hervas-Stubbs

, Rueda

, Lopez

, Leclerc

. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol, 2007; 178:2361–2369.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.09 MB

0.00 MB

Baculovirus-Produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge

Abstract

Get full access to this article

References

Supplementary Material